Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta‐analysis

Cited by (1,004)

Items 201–300 of 1,004

1. Non‐alcoholic fatty liver disease and type 2 diabetes: An update
   Chi‐Ho Lee, David Tak Wai Lui, Karen SL Lam · 2022 · Journal of Diabetes Investigation
2. Nonalcoholic Fatty Liver Disease in Children: Unique Considerations and Challenges
   Dana L. Goldner, Joel E. Lavine · 2020 · Gastroenterology
3. EASL–EASD–EASO clinical practice guidelines for the management of non-alcoholic fatty liver disease in severely obese people: do they lead to over-referral?
   Emilie Blond, Emmanuel Disse, Charlotte Cuerq, Jocelyne Drai, Pierre‐Jean Valette, Martine Laville, Charles H. Thivolet, C. Simon, Cyrielle Caussy · 2017 · Diabetologia
4. Projected increase in obesity and non‐alcoholic‐steatohepatitis–related liver transplantation waitlist additions in the United States
   Neehar D. Parikh, Wesley J. Marrero, Jingyuan Wang, Justin Steuer, Elliot B. Tapper, Monica A. Konerman, Amit G. Singal, David W. Hutton, Eunshin Byon, Mariel S. Lavieri · 2017 · Hepatology
5. Agreement between wedged hepatic venous pressure and portal pressure in non-alcoholic steatohepatitis-related cirrhosis
   José Ferrusquía‐Acosta, Octavi Bassegoda, Laura Turco, Enric Reverter, Monica Pellone, Marcello Bianchini, Valeria Pérez‐Campuzano, Enric Ripoll, Ángeles García‐Criado, Isabel Graupera et al. · 2020 · Journal of Hepatology
6. Diagnostic Accuracy of FibroScan and Factors Affecting Measurements
   Satoshi Oeda, Kenichi Tanaka, Ayaka Oshima, Yasue Matsumoto, Eisaburo Sueoka, Hirokazu Takahashi · 2020 · Diagnostics
7. Cenicriviroc for the treatment of non-alcoholic steatohepatitis and liver fibrosis
   Frank Tacke · 2018 · Expert Opinion on Investigational Drugs
8. Patatin‐Like Phospholipase Domain‐Containing Protein 3 I148M and Liver Fat and Fibrosis Scores Predict Liver Disease Mortality in the U.S. Population
   Aynur Ünalp–Arida, Constance E. Ruhl · 2019 · Hepatology
9. Preparing for the NASH Epidemic: A Call to Action
   Fasiha Kanwal, Jay H. Shubrook, Zobair M. Younossi, Yamini Natarajan, Elisabetta Bugianesi, Mary Eugenia Rinella, Stephen A. Harrison, Christos Socrates Mantzoros, Kim M. Pfotenhauer, Samuel Klein et al. · 2021 · Gastroenterology
10. The steatosis‐associated fibrosis estimator (SAFE) score: A tool to detect low‐risk NAFLD in primary care
    Pimsiri Sripongpun, W. Ray Kim, Ajitha Mannalithara, Vivek Charu, Anna A. Vidovszky, Steven M. Asch, Manisha Desai, Sun H. Kim, Allison J. Kwong · 2022 · Hepatology
11. Metabolic dysfunction-associated steatotic liver disease and the heart
    Stan Driessen, Sven Francque, Stefan D. Anker, Manuel Castro Cabezas, Diederick E. Grobbee, Maarten E. Tushuizen, Adriaan Georgius Holleboom · 2023 · Hepatology
12. Bile acid and receptors: biology and drug discovery for nonalcoholic fatty liver disease
    Tingying Jiao, Yuandi Ma, Xiaozhen Guo, Yun‐Fei Ye, Cen Xie · 2022 · Acta Pharmacologica Sinica
13. STING expression in monocyte-derived macrophages is associated with the progression of liver inflammation and fibrosis in patients with nonalcoholic fatty liver disease
    Xiaoxiao Wang, Huiying Rao, Jingmin Zhao, Aileen Wee, Xiaohe Li, Ran Fei, Rui Huang, Chaodong Wu, Feng Liu, Lai Wei · 2019 · Laboratory Investigation
14. Development and Validation of a Score for Fibrotic Nonalcoholic Steatohepatitis
    Federica Tavaglione, Oveis Jamialahmadi, Antonio De Vincentis, Sami U. Qadri, Mohammad Erfan Mowlaei, Rosellina Margherita Mancina, Ester Ciociola, Simone Carotti, Giuseppe Perrone, Vincenzo Bruni et al. · 2022 · Clinical Gastroenterology and Hepatology
15. Novel antisense inhibition of diacylglycerol O-acyltransferase 2 for treatment of non-alcoholic fatty liver disease: a multicentre, double-blind, randomised, placebo-controlled phase 2 trial
    Rohit Seth Loomba, Erin S. Morgan, Lynnetta M. Watts, Shuting Xia, Lisa A. Hannan, Richard S. Geary, Brenda F. Baker, Sanjay Bhanot · 2020 · The Lancet. Gastroenterology & hepatology
16. A randomized, double-blind, multicenter, phase 2b study to evaluate the safety and efficacy of a combination of tropifexor and cenicriviroc in patients with nonalcoholic steatohepatitis and liver fibrosis: Study design of the TANDEM trial
    Marcos C. Pedrosa, Star Seyedkazemi, Sven Francque, Arun Jayant Sanyal, Mary Eugenia Rinella, Michael Charlton, Rohit Seth Loomba, Vlad Ratziu, Jossy George Kochuparampil, Laurent Fischer et al. · 2019 · Contemporary Clinical Trials
17. Hepatic sexual dimorphism — implications for non-alcoholic fatty liver disease
    Philippe Lefèbvre, Bart Staels · 2021 · Nature Reviews Endocrinology
18. Lean individuals with NAFLD have more severe liver disease and poorer clinical outcomes (NASH-CO Study)
    Oumarou Nabi, Nathanaël Lapidus, Jérôme Boursier, Victor de Lédinghen, Jean‐Michel Petit, Sofiane Kab, Adeline Renuy, Marie Zins, Karine Lacombe, Lawrence Serfaty · 2023 · Hepatology
19. Amphiregulin from regulatory T cells promotes liver fibrosis and insulin resistance in non-alcoholic steatohepatitis
    Savage, Thomas M., Fortson, Katherine T., de los Santos-Alexis, Kenia, Oliveras-Alsina, Angelica, Rouanne, Mathieu, Rae, Sarah S., Gamarra, Jennifer R., Shayya, Hani, Kornberg, Adam, Cavero, Renzo et al. · 2024 · Immunity
20. Nonalcoholic fatty liver disease (NAFLD) and associated mortality in individuals with type 2 diabetes, pre-diabetes, metabolically unhealthy, and metabolically healthy individuals in the United States
    Golabi, Pegah, Paik, James M., Kumar, Ameeta, Al Shabeeb, Reem, Eberly, Kathrine E., Cusi, Kenneth, GunduRao, Nagashree, Younossi, Zobair M. · 2023 · Metabolism
21. Maladaptive regeneration - the reawakening of developmental pathways in NASH and fibrosis
    Zhu, Changyu, Tabas, Ira, Schwabe, Robert F., Pajvani, Utpal B. · 2021 · Nature Reviews Gastroenterology & Hepatology
22. Hepatic stellate cells: balancing homeostasis, hepatoprotection and fibrogenesis in health and disease
    Schwabe, Robert F., Brenner, David A. · 2025 · Nature Reviews Gastroenterology & Hepatology
23. Silybin inhibits NLRP3 inflammasome assembly through the NAD + /SIRT2 pathway in mice with nonalcoholic fatty liver disease
    Bangling Zhang, Dan Xu, Linlin She, Zixia Wang, Na Yang, Runbin Sun, Yirui Zhang, Caixia Yan, Qingli Wei, Jiye Aa et al. · 2017 · The FASEB Journal
24. Role of imaging-based biomarkers in NAFLD: Recent advances in clinical application and future research directions
    Rohit Seth Loomba · 2017 · Journal of Hepatology
25. Defining the serum proteomic signature of hepatic steatosis, inflammation, ballooning and fibrosis in non-alcoholic fatty liver disease
    Arun Jayant Sanyal, Stephen A. Williams, Joel E. Lavine, Brent A. Neuschwander‐Tetri, Leigh E. Alexander, Rachel M. Ostroff, Hannah Biegel, Kris V. Kowdley, Naga Chalasani, Srinivasan Dasarathy et al. · 2022 · Journal of Hepatology
26. Non-invasive testing and risk-stratification in patients with MASLD
    Mirko Zoncapè, Antonio Liguori, Emmanuel A. Tsochatzis · 2024 · European Journal of Internal Medicine
27. Clinical and Economic Burden of Nonalcoholic Fatty Liver Disease and Nonalcoholic Steatohepatitis
    Zobair M. Younossi, Linda L Henry, Haley Bush, Alita Mishra · 2017 · Clinics in Liver Disease
28. Statin use is associated with lower prevalence of advanced liver fibrosis in patients with type 2 diabetes
    Stefano Ciardullo, Gianluca Perseghin · 2021 · Metabolism
29. Liver stiffness thresholds to predict disease progression and clinical outcomes in bridging fibrosis and cirrhosis
    Loomba, Rohit, Huang, Daniel Q., Sanyal, Arun J, Anstee, Quentin Mark, Trauner, Michael, Lawitz, Eric J, Ding, Dora, Ma, Lily, Jia, Catherine, Billin, Andrew et al. · 2023 · Gut
30. A randomized, double-blind, placebo-controlled phase IIa trial of efruxifermin for patients with compensated NASH cirrhosis
    Harrison, Stephen A., Ruane, Peter J., Freilich, Bradley, Neff, Guy, Patil, Rashmee, Behling, Cynthia, Hu, Chen, Shringarpure, Reshma, de Temple, Brittany, Fong, Erica et al. · 2023 · JHEP Reports
31. Head-to-head comparison between MEFIB, MAST, and FAST for detecting stage 2 fibrosis or higher among patients with NAFLD
    Beom Kyung Kim, Nobuharu Tamaki, Kento Imajo, Masato Yoneda, Nancy Sutter, Jinho Jung, Lin Tuo, Xin Ming Tu, Jaclyn Bergstrom, Khang Nguyen et al. · 2022 · Journal of Hepatology
32. Underappreciation of non‐alcoholic fatty liver disease by primary care clinicians: limited awareness of surrogate markers of fibrosis
    Preya Janubhai Patel, Xuan Banh, Leigh Ula Horsfall, Kelly Lee Hayward, Fabrina Hossain, Tracey Johnson, Katherine Anne Stuart, Nigel Neil Brown, Nivene Saad, Andrew Donald Clouston et al. · 2017 · Internal Medicine Journal
33. A clinical overview of non‐alcoholic fatty liver disease: A guide to diagnosis, the clinical features, and complications—What the non‐specialist needs to know
    Mark Dhinesh Muthiah, Ng Cheng Han, Arun Jayant Sanyal · 2021 · Diabetes Obesity and Metabolism
34. BMS-986263 in patients with advanced hepatic fibrosis: 36-week results from a randomized, placebo-controlled phase 2 trial
    Lawitz, Eric J., Shevell, Diane E., Tirucherai, Giridhar S., Du, Shuyan, Chen, Warner, Kavita, Uma, Coste, Angie, Poordad, Fred, Karsdal, Morten, Nielsen, Mette et al. · 2022 · Hepatology
35. Impact of NAFLD on the Incidence of Cardiovascular Diseases in a Primary Care Population in Germany
    Christian Labenz, Yvonne Huber, Maurice Stephan Michel, Michael C Nagel, Peter R. Galle, Karel Kostev, Jörn Markus Schattenberg · 2019 · Digestive Diseases and Sciences
36. Predictors of advanced fibrosis in non‐cirrhotic non‐alcoholic fatty liver disease in Germany
    Christian Labenz, Yvonne Huber, Eva Kalliga, Michael Nagel, Christian Ruckes, Beate Katharina Straub, Peter R. Galle, Marcus‐Alexander Wörns, Quentin Mark Anstee, Detlef Schuppan et al. · 2018 · Alimentary Pharmacology & Therapeutics
37. Health-related Quality of Life in Nonalcoholic Fatty Liver Disease Associates With Hepatic Inflammation
    Yvonne Huber, Marie Boyle, Kate Hallsworth, DINA G. TINIAKOS, Beate Katharina Straub, Christian Labenz, Christian Ruckes, Peter R. Galle, Manuel Romero‐Gómez, Quentin Mark Anstee et al. · 2018 · Clinical Gastroenterology and Hepatology
38. Nonalcoholic steatohepatitis (NASH) – current treatment recommendations and future developments
    Elke Roeb, Andreas Geier · 2019 · Zeitschrift für Gastroenterologie
39. NAFLD in the Elderly
    Saleh A Alqahtani, Jörn Markus Schattenberg · 2021 · Clinical Interventions in Aging
40. Natural history of NASH and HCC
    Francesco Negro · 2020 · Liver International
41. Role of Noninvasive Tests in Clinical Gastroenterology Practices to Identify Patients With Nonalcoholic Steatohepatitis at High Risk of Adverse Outcomes: Expert Panel Recommendations
    Zobair M. Younossi, Mazen Noureddin, David Bernstein, Paul Yien Kwo, Mark W. Russo, Mitchell L. Shiffman, Ziad H Younes, Manal F. Abdelmalek · 2020 · The American Journal of Gastroenterology
42. The purinergic P2Y14 receptor links hepatocyte death to hepatic stellate cell activation and fibrogenesis in the liver
    Mederacke, Ingmar, Filliol, Aveline, Affo, Silvia, Nair, Ajay, Hernandez, Celine, Sun, Qiuyan, Hamberger, Florian, Brundu, Francesco, Chen, Yu, Ravichandra, Aashreya et al. · 2022 · Science Translational Medicine
43. Systematic review with meta‐analysis: the significance of histological disease severity in lean patients with nonalcoholic fatty liver disease
    Silvia C. Sookoian, Carlos Jose Pirola · 2017 · Alimentary Pharmacology & Therapeutics
44. Mortality of NAFLD According to the Body Composition and Presence of Metabolic Abnormalities
    Pegah Golabi, James M. Paik, Tamoore Arshad, Youssef Younossi, Alita Mishra, Zobair M. Younossi · 2020 · Hepatology Communications
45. Indian National Association for Study of the Liver (INASL) Guidance Paper on Nomenclature, Diagnosis and Treatment of Nonalcoholic Fatty Liver Disease (NAFLD)
    Ajay Kumar. Duseja, Shivaram Prasad Singh, Arka De, Kaushal Madan, Padaki Nagaraja Rao, Akash Shukla, Gourdas Choudhuri, Sanjiv Saigal, S. Shalimar, Anil Arora et al. · 2022 · Journal of Clinical and Experimental Hepatology
46. Depression is associated with non‐alcoholic fatty liver disease among adults in the United States
    Donghee Kim, Eric R. Yoo, Andrew A. Li, Sean P. Tighe, George T. Cholankeril, Stephen A. Harrison, Aijaz Ahmed · 2019 · Alimentary Pharmacology & Therapeutics
47. Transcriptional Dynamics of Hepatic Sinusoid‐Associated Cells After Liver Injury
    Mike Krogh Terkelsen, Sofie Marchsteiner Bendixen, Daniel Hansen, Emma A.H. Scott, Andreas F. Moeller, Ronni Nielsen, Susanne Mandrup, Anders Grønnegaard Schlosser, Thomas Levin Andersen, Grith Lykke Sørensen et al. · 2020 · Hepatology
48. Hydroxysteroid 17-β dehydrogenase 13 variant increases phospholipids and protects against fibrosis in nonalcoholic fatty liver disease
    Panu K. Luukkonen, Taru Tukiainen, Anne Juuti, Henna E. Sammalkorpi, P.A. Nidhina Haridas, Onni J Niemelä, Johanna T. Arola, Marju Orho‐Melander, Antti Hakkarainen, Petri T. Kovanen et al. · 2020 · JCI Insight
49. The burden of non-alcoholic steatohepatitis: A systematic review of health-related quality of life and patient-reported outcomes
    Zobair M. Younossi, Priya Aggarwal, Ichhya Shrestha, João Diogo da Rocha Fernandes, Pierre Johansen, Margarida Augusto, Sunita Nair · 2022 · JHEP Reports
50. Aktualisierte S2k-Leitlinie nicht-alkoholische Fettlebererkrankung der Deutschen Gesellschaft für Gastroenterologie, Verdauungs- und Stoffwechselkrankheiten (DGVS) – April 2022 – AWMF-Registernummer: 021–025
    Elke Roeb, Ali E. Canbay, Frank Tacke, Heike Bantel, Jörg Bojunga, Jan de Laffolie, Münevver Demir, Ulrike Walburga Denzer, A Geier, Wolf Peter Hofmann et al. · 2022 · Zeitschrift für Gastroenterologie
51. Outcomes of NAFLD and MAFLD: Results from a community-based, prospective cohort study
    Madunil Anuk Niriella, Dileepa Senajith Ediriweera, Anuradhani Kasturiratne, Shamila De Silva, Anuradha Supun Dassanayaka, Arjuna Priyadarsin De Silva, Norihiro Kato, Arunasalam Pathmeswaran, Ananda Rajitha Wickramasinghe, Hithanadura Janaka de Silva · 2021 · PLoS ONE
52. The NLRP3 inflammasome in alcoholic and nonalcoholic steatohepatitis
    Knorr, Jana, Wree, Alexander, Tacke, Frank, Feldstein, Ariel E. · 2020 · Seminars in Liver Disease
53. Metabolic Stress, Autophagy, and Cardiovascular Aging: from Pathophysiology to Therapeutics
    Jun Tao Ren, James R. Sowers, Yingmei Zhang · 2018 · Trends in Endocrinology and Metabolism
54. DNA Methylation in Nonalcoholic Fatty Liver Disease
    Jeongeun Hyun, Youngmi Jung · 2020 · International Journal of Molecular Sciences
55. Clinical Outcomes in Biopsy-Proven Nonalcoholic Fatty Liver Disease Patients: A Multicenter Registry-based Cohort Study
    Hideki Fujii, Michihiro Iwaki, Hideki Hayashi, Hidenori Toyoda, Satoshi Oeda, Hideyuki Hyogo, Miwa Kawanaka, Asahiro Morishita, Kensuke Munekage, Kazuhito Kawata et al. · 2022 · Clinical Gastroenterology and Hepatology
56. Causes and risk profiles of mortality among individuals with nonalcoholic fatty liver disease
    Peter Konyn, Aijaz Ahmed, Donghee Kim · 2022 · Clinical and Molecular Hepatology
57. Impact of Obesity and Alanine Aminotransferase Levels on the Diagnostic Accuracy for Advanced Liver Fibrosis of Noninvasive Tools in Patients With Nonalcoholic Fatty Liver Disease
    Salvatore Petta, Vincent Wai‐Sun Wong, Elisabetta Bugianesi, Anna Ludovica Fracanzani, Calogero Cammà, Jean‐Baptiste Hiriart, Grace Lai‐Hung Wong, Julien Vergniol, Anthony W.H. Chan, Aurora Giannetti et al. · 2019 · The American Journal of Gastroenterology
58. Elafibranor: a potential drug for the treatment of nonalcoholic steatohepatitis (NASH)
    Menso Westerouen van Meeteren, Joost P.H. Drenth, Eric T.T.L. Tjwa · 2019 · Expert Opinion on Investigational Drugs
59. AGA Clinical Practice Update on Bariatric Surgery in Cirrhosis: Expert Review
    Patton, Heather, Heimbach, Julie, McCullough, Arthur · 2021 · Clinical Gastroenterology and Hepatology
60. Inflammation and immunity in liver homeostasis and disease: a nexus of hepatocytes, nonparenchymal cells and immune cells
    2025
61. Prevalence and severity of nonalcoholic fatty liver disease by transient elastography: Genetic and metabolic risk factors in a general population
    Salvatore Petta, Vito Di Marco, Rosaria Maria Pipitone, Stefania Grimaudo, Carola Buscemi, Antonio Craxı̀, Silvio Buscemi · 2018 · Liver International
62. Transcriptional regulation of Hepatic Stellate Cell activation in NASH
    Marcher, Ann-Britt, Bendixen, Sofie M., Terkelsen, Mike K., Hohmann, Sonja S., Hansen, Maria H., Larsen, Bjørk D., Mandrup, Susanne, Dimke, Henrik, Detlefsen, Sönke, Ravnskjaer, Kim · 2019 · Scientific Reports
63. Serum Interleukin‐8, Osteopontin, and Monocyte Chemoattractant Protein 1 Are Associated With Hepatic Fibrosis in Patients With Nonalcoholic Fatty Liver Disease
    Oliver Glass, Ricardo Henao, Keyur Patel, Cynthia D. Guy, Hans J. Gruss, Wing‐Kin Syn, Cynthia A. Moylan, Robert D. Streilein, Russell P. Hall, Anna Mae Diehl et al. · 2018 · Hepatology Communications
64. Dietary Interventions in Patients With Non-alcoholic Fatty Liver Disease: A Systematic Review and Meta-Analysis
    Veera Houttu, Susanne Csader, Max Nieuwdorp, Adriaan Georgius Holleboom, Ursula Schwab · 2021 · Frontiers in Nutrition
65. Risk of cardiovascular disease in patients with fatty liver disease as defined from the metabolic dysfunction associated fatty liver disease or nonalcoholic fatty liver disease point of view: a retrospective nationwide claims database study in Japan
    Masato Yoneda, Takuma Yamamoto, Yasushi Honda, Kento Imajo, Yuji Ogawa, Takaomi Kessoku, Takashi Kobayashi, Asako Nogami, Takuma Higurashi, Shingo Kato et al. · 2021 · Journal of Gastroenterology
66. Improvement of non‐invasive markers of NAFLD from an individualised, web‐based exercise program
    Yvonne Huber, Daniel Pfirrmann, I Gebhardt, Christian Labenz, Nadine Gehrke, Beate Katharina Straub, Christian Ruckes, Heike Bantel, Eugeni Belda, Karine Clément et al. · 2019 · Alimentary Pharmacology & Therapeutics
67. Fibrosis‐4 Index as an Independent Predictor of Mortality and Liver‐Related Outcomes in NAFLD
    Joana Vieira Barbosa, Scott C. Milligan, Andrew Frick, Jeremy Broestl, Zobair M. Younossi, Nezam H. Afdhal, Michelle Lai · 2021 · Hepatology Communications
68. Gut microbiota and metabolic biomarkers in metabolic dysfunction–associated steatotic liver disease
    Qichen Long, Fengming Luo, Binghui Li, Ziyang Li, Zhe Guo, Zhiyang Chen, Weimin Wu, Min Hu · 2024 · Hepatology Communications
69. Pathophysiological underpinnings of metabolic dysfunction-associated steatotic liver disease
    Mohammad Shafi Kuchay, Narendra Singh Choudhary, Bruno Ramos‐Molina · 2025 · American Journal of Physiology-Cell Physiology
70. Systematic review with network meta-analysis: comparative efficacy of pharmacologic therapies for fibrosis improvement and resolution of NASH
    Majzoub, Abdul M., Nayfeh, Tarek, Barnard, Abbey, Munaganuru, Nagambika, Dave, Shravan, Singh, Siddharth, Murad, Mohammad Hassan, Loomba, Rohit · 2021 · Alimentary Pharmacology & Therapeutics
71. Non‐invasive tests for liver fibrosis in NAFLD: Creating pathways between primary healthcare and liver clinics
    Laurent Castéra · 2020 · Liver International
72. Clinical assessment for high‐risk patients with non‐alcoholic fatty liver disease in primary care and diabetology practices
    Zobair M. Younossi, Kathleen E. Corey, Naim Alkhouri, Mazen Noureddin, Ira M. Jacobson, Brian P Lam, Stephen C. Clement, Rita Basu, Stuart C. Gordon, Natarajan Ravendhra et al. · 2020 · Alimentary Pharmacology & Therapeutics
73. Nonalcoholic Fatty Liver Disease Prevalence Trends Among Adolescents and Young Adults in the United States, 2007‐2016
    Tamoore Arshad, James M. Paik, Rakesh Biswas, Saleh A. Alqahtani, Linda L Henry, Zobair M. Younossi · 2021 · Hepatology Communications
74. Review article: non‐alcoholic fatty liver disease and cardiovascular diseases: associations and treatment considerations
    Stergios A. Pοlyzos, Stergios Kechagias, Emmanuel A. Tsochatzis · 2021 · Alimentary Pharmacology & Therapeutics
75. 2026 AHA/ACC/ADA/ASN Guideline for the Prevention, Detection, Evaluation, and Management of Cardiovascular-Kidney-Metabolic Syndrome
    Ndumele, Chiadi E., Rodriguez, Fatima, Dixon, Dave L., Khan, Sadiya S., Mukherjee, Debabrata, Bajaj, Mandeep, Bangalore, Sripal, Bozkurt, Biykem, Breathett, Khadijah, Clarke, Shoa L. et al. · 2026 · JACC
76. From the origin of NASH to the future of metabolic fatty liver disease
    Andreas Geier, DINA G. TINIAKOS, Helmut Denk, Michael A Trauner · 2021 · Gut
77. Ceruloplasmin gene variants are associated with hyperferritinemia and increased liver iron in patients with NAFLD
    Elena Corradini, Elena Buzzetti, Paola Dongiovanni, Stefania Scarlini, Angela Caleffi, Serena Pelusi, Isabella Bernardis, Paolo Ventura, Raffaela Rametta, Elena Tenedini et al. · 2021 · Journal of Hepatology
78. Advancements in pharmacological treatment of NAFLD/MASLD: a focus on metabolic and liver-targeted interventions
    Stefano Ciardullo, Emanuele Muraca, Michela Vergani, Pietro Invernizzi, Gianluca Perseghin · 2023 · Gastroenterology report
79. American College of Sports Medicine (ACSM) International Multidisciplinary Roundtable report on physical activity and nonalcoholic fatty liver disease
    Stine, Jonathan G., Long, Michelle T., Corey, Kathleen E., Sallis, Robert E., Allen, Alina M., Armstrong, Matthew J., Conroy, David E., Cuthbertson, Daniel J., Duarte-Rojo, Andres, Hallsworth, Kate et al. · 2023 · Hepatology Communications
80. Screening for Nonalcoholic Fatty Liver Disease in Inflammatory Bowel Diseases: A Cohort Study Using Transient Elastography
    Chiara Saroli Palumbo, Sophie Restellini, Che‐Yung Chao, Achuthan Aruljothy, Carolyne Lemieux, Gary Wild, Waqqas Afif, Peter Laszlo Lakatos, Alain Bitton, Sila Cocciolillo et al. · 2018 · Inflammatory Bowel Diseases
81. Interactions between the cecal microbiota and non-alcoholic steatohepatitis using laying hens as the model
    H. Hamid, J.Y. Zhang, W.X. Li, Chunfa Liu, Meiyue Li, L.H. Zhao, Cheng Ji, Q.G. Ma · 2019 · Poultry Science
82. Impact of Implementing a “FIB‐4 First” Strategy on a Pathway for Patients With NAFLD Referred From Primary Care
    Tracy Davyduke, Puneeta Tandon, Mustafa Al‐Karaghouli, Juan G. Abraldeṣ, Mang M. Ma · 2019 · Hepatology Communications
83. Improvement of hepatic fibrosis and patient‐reported outcomes in non‐alcoholic steatohepatitis treated with selonsertib
    Zobair M. Younossi, Maria Stepanova, Eric Lawitz, Michael Charlton, Rohit Seth Loomba, Robert P. Myers, Mani G. Subramanian, John G. McHutchison, Zachary D Goodman · 2018 · Liver International
84. Pathogenesis of Insulin Resistance and Atherogenic Dyslipidemia in Nonalcoholic Fatty Liver Disease
    Daud H. Akhtar, Umair Iqbal, Luis Miguel Vazquez‐Montesino, Brittany Burns Dennis, Aijaz Ahmed · 2019 · Journal of Clinical and Translational Hepatology
85. Liver biopsy-based validation, confirmation and comparison of the diagnostic performance of established and novel non-invasive steatotic liver disease indexes: Results from a large multi-center study
    Matina Kouvari, Laura Valenzuela‐Vallejo, Valentina Guatibonza-García, Stergios A. Pοlyzos, Yixiang Deng, Michail Kokkorakis, Melih Agraz, Sophia C. Mylonakis, Angeliki Katsarou, Ornella Verrastro et al. · 2023 · Metabolism
86. Insulin resistance and hyperandrogenism drive steatosis and fibrosis risk in young females with PCOS
    Salvatore Petta, Alessandro Ciresi, Jessica Bianco, Vincenzo Geraci, Roberta Boemi, Luigi Galvano, Franco Magliozzo, Giovanni Merlino, Antonio Craxı̀, Carla Santos de Souza Giordano · 2017 · PLoS ONE
87. The metabolic basis of nonalcoholic steatohepatitis
    Manu V. Chakravarthy, Brent A. Neuschwander‐Tetri · 2020 · Endocrinology Diabetes & Metabolism
88. Ethnic influence on nonalcoholic fatty liver disease prevalence and lack of disease awareness in the United States, 2011–2016
    Michael Huan Le, Yee Hui Yeo, Ramsey C Cheung, Vincent Wai‐Sun Wong, Mindie H. Nguyen · 2020 · Journal of Internal Medicine
89. Moderate alcohol consumption is associated with advanced fibrosis in non-alcoholic fatty liver disease and shows a synergistic effect with type 2 diabetes mellitus
    Julia Blomdahl, Patrik Nasr, Mattias Ekstedt, Stergios Kechagias · 2020 · Metabolism
90. Disease State Transition Probabilities Across the Spectrum of NAFLD: A Systematic Review and Meta-Analysis of Paired Biopsy or Imaging Studies
    Phuc Le, Julia Yang Payne, Lu Zhang, Abhishek Deshpande, Michael B. Rothberg, Naim Alkhouri, William H. Herman, Adrián Vladimir Hernández, Mary C. Schleicher, Wen Ye et al. · 2022 · Clinical Gastroenterology and Hepatology
91. Role of lactate and lactate metabolism in liver diseases (Review)
    Shun Yao, Hongyu Chai, Ting Tao, Li Rita Zhang, Xingyue Yang, Xin Li, Zhiqiang Yi, Yongfeng Wang, Jiaxin An, Guorong Wen et al. · 2024 · International Journal of Molecular Medicine
92. The degree of hepatic steatosis associates with impaired cardiac and autonomic function
    David Houghton, Paweł Zalewski, Kate Hallsworth, Sophie Cassidy, Christian Thoma, Leah Avery, Joanna Słomko, Timothy Hardy, Alastair D. Burt, DINA G. TINIAKOS et al. · 2019 · Journal of Hepatology
93. New drugs for NAFLD: lessons from basic models to the clinic
    Katharina C. Reimer, Alexander Wree, Christoph Roderburg, Frank Tacke · 2019 · Hepatology International
94. NAFLD in the Elderly
    Saleh A. Alqahtani, Jörn Markus Schattenberg · 2021 · Dove Medical Press (Taylor and Francis Group)
95. Predicting NAFLD prevalence in the United States using National Health and Nutrition Examination Survey 2017–2018 transient elastography data and application of machine learning
    Mazen Noureddin, Fady Y. Ntanios, Deepa Malhotra, Katherine Hoover, Birol Emir, Euan James McLeod, Naim Alkhouri · 2022 · Hepatology Communications
96. Diagnostic accuracy of FibroScan-AST (FAST) score for the non-invasive identification of patients with fibrotic non-alcoholic steatohepatitis: a systematic review and meta-analysis
    Federico Ravaioli, Elton Dajti, Alessandro Mantovani, Philip Noel Newsome, Giovanni Targher, Antonio Colecchia · 2023 · Gut
97. Comparison of murine steatohepatitis models identifies a dietary intervention with robust fibrosis, ductular reaction, and rapid progression to cirrhosis and cancer
    Wei, Guangyan, An, Ping, Vaid, Kahini A., Nasser, Imad, Huang, Pinzhu, Tan, Li, Zhao, Shuangshuang, Schuppan, Detlef, Popov, Yury V. · 2020 · American Journal of Physiology-Gastrointestinal and Liver Physiology
98. Serum metabolites detect the presence of advanced fibrosis in derivation and validation cohorts of patients with non-alcoholic fatty liver disease
    Cyrielle Caussy, Veeral H. Ajmera, Puneet Puri, Cynthia L. Hsu, Shirin Bassirian, Mania Mgdsyan, Seema Singh, Claire Faulkner, Mark A. Valasek, Emily Rizo et al. · 2018 · Gut
99. Pharmacological Treatment for Non-alcoholic Fatty Liver Disease
    Sven Francque, Luisa Vonghia · 2019 · Advances in Therapy
100. Clinical Utility of an Increase in Magnetic Resonance Elastography in Predicting Fibrosis Progression in Nonalcoholic Fatty Liver Disease
     Veeral H. Ajmera, Amy Liu, Seema Singh, Georg Yachoa, Matthew Ramey, Meera Bhargava, Ava Zamani, Scarlett J. Lopez, Neeraj Mangla, Ricki Bettencourt et al. · 2019 · Hepatology